Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.
You may also be interested in...
Novartis Stockpiling Priority Review Vouchers
Firm picks up second PRV with purchase from Ultragenyx, which is expected to use the $130m to help advance its rare disease development pipeline.
Novartis Stockpiling Priority Review Vouchers
Firm picks up second PRV with purchase from Ultragenyx, which is expected to use the $130m to help advance its rare disease development pipeline.
Voucher Does Not Guarantee A Priority Review, FDA Says
Final guidance on the tropical disease priority review voucher program says FDA will adhere to priority review goals, which allow agency to complete some outside the stated time frame.